SmartMed Technologies announces Hana Kotaro as Director of Economic Research

SmartMed Technologies of South Korea today announced that Hana Kotaro has joined the firm as Director of Economic Research.

Online PR News – 15-July-2021 – YEONGDEUNGPO-GU/SEOUL – In this newly created role, Hana Kotaro will lead research activity across SmartMed Technologies' medical investment platform.

With responsibility for research, Hana will make a key contribution to the firm, heading the economic research division, providing portfolio managers with investable ideas across all asset classes. In addition, Hana Kotaro will play a prominent role in presenting investment views to the Board of SmartMed Technologies.

SmartMed Technologies' Vice President of Research & Development, Ms. Ji-hye Yeong commented on the welcome addition saying "I am delighted to welcome a professional of Hana's calibre to the firm. Having a powerful global research function gives our investment teams a crucial edge as they strive to deliver superior performance to our clients. Hana will help us to make optimal use of our global research resources as well as the best external research."

Hana Kotaro was most recently Director of Economic Strategy at The Master Trust Bank of Japan. Before that, he served as Director of Research for Emerging Markets for The Shenshu Bank across different asset classes.

About Us - SmartMed Technologies

SmartMed Technologies is a pioneering bioinformatics medical research and development company focused on delivering innovative medical products through artificial intelligence technology to combat prevalent, rare and emerging diseases.

Based in Seoul, our team collects and analyzes big data, utilizing artificial intelligence to gain insight into complex diseases such as leukemia and different cancers. Our approach centers on genome integration with high-performance computers and deep artificial intelligence learning.

With our advanced technology, we have been able to cut costs arising from industry trial-and-error procedures; with the integration of supercomputers into our work, we are able to run more comprehensive simulations, better target proteins, discover new drug compounds for a multitude of diseases, and generally increase our capacity for successful drug development.

With international recognition for our research and projects, some in collaboration with world-renowned institutions, we consistently aim to develop our understanding in the medical field through artificial intelligence and advanced clinical trials.